nbi-74788
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 10, 2018 (NCT03525886)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanocortin receptor 2INHIBITOR
MC2R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04045145 | Phase 2 | Aug 31, 2019 | Neurocrine Biosciences |
| NCT03525886 | Phase 2 | Apr 10, 2018 | Neurocrine Biosciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurocrine Biosciences | For profit | 2 | 2 | 1 | 2018 |
1 organizations
Page 1 / 1